Maxim Group Reaffirms Their Buy Rating on Milestone Scientific

By Ryan Adsit

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Milestone Scientific (NYSE: MLSS) today and set a price target of $4. The company’s shares opened today at $1.55.

Vendetti observed:

“Today, before the Market open, MLSS announced FDA 510(k) clearance for its CompuFlo epidural instrument (EI). The clearance was supported by the CompuFlo Assessment (COMPASS) clinical study completed in June 2016. On June 2, 2017, MLSS announced an asset purchase agreement with APAD Octrooi to purchase intellectual property (IP) for €2.2M in restricted common stock. The IP is related to the seller’s computer controlled injection instrument. On June 6, 2017, MLSS agreed to sell its 40% interest in Milestone China Ltd. to Solee Science & Technology U.S.A., Ltd.”

According to, Vendetti is a 5-star analyst with an average return of 16.9% and a 68.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Xtant Medical Holdings, Quest Diagnostics Inc, and Syneron Medical Ltd.

Milestone Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $4.

The company has a one year high of $3.04 and a one year low of $1.10. Currently, Milestone Scientific has an average volume of 17.95K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Milestone Scientific, Inc. engages in pioneering proprietary, innovative technological systems and solutions for the medical and dental markets. It develops, manufactures, markets and sells computer controlled system for the improved and painless delivery of local anesthetic. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The company was founded in August 17, 1989 and is headquartered in Livingston, NJ.